The company said brilaroxazine, the drug aimed at treating schizophrenia, also has enrollment across sites in Europe.
2 Likes
Never heard of it. But sounds promising!
1 Like
“No treatment-related serious adverse events or major safety and tolerability concerns have been observed to date in this double-blind phase 3 study. We remain highly encouraged by the potential for brilaroxazine”
Sounds great on paper!
2 Likes
May be similar to Abilify. Completion of phase 3 trial estimated at December 2023.
Wiki of drug: Brilaroxazine - Wikipedia
1 Like
Partial dopamine agonist dont really interest me. I was kinda interested in teying abilify since it was a partial agonist but it wound up being rhe same as risperidone.
2 Likes